MedTrace Logo

STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY

NCT05286138 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2022-04-01

No results posted yet for this study

Summary

The Trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are more frequent in patients with hemoglobinopathies. Still, in relation to tumor pathology, the study will evaluate any differences between the different types of hemoglobinopathy and will investigate the association between the appearance of neoplasms and risk factors such as age, sex, iron accumulation markers, history of bone marrow transplant, and others.

Conditions

  • Malignacy, Hemoglobinopathie

Sponsors & Collaborators

  • Società Italiana Talassemie ed Emoglobinopatie

    lead OTHER

Principal Investigators

  • RAFFAELLA ORIGA, MD · Azienda Ospedaliero Universitaria di Cagliari

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-02-28
Completion
2052-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05286138 on ClinicalTrials.gov